You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Effectuez un dépistage du virus de l'hépatite B chez tous les patients cancéreux débutant un traitement systémique. Apprenez-en davantage sur le dépistage et la gestion du virus de l'hépatite B.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

pembrolizumab

( PEM broe LIZ ue mab )
Other Name(s): Keytruda®
Apparence: solution mixed into larger bags of fluids

Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.

Drug Monograph

aoû 2023
Eligibility Forms
pdf download Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab pdf download Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab pdf download Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line) pdf download Pembrolizumab - First-line Treatment of Advanced Esophageal and Esophagogastric Junction Carcinoma pdf download Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma pdf download Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer pdf download Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck pdf download Pembrolizumab (Adult and Pediatric) - Relapsed cHL Post-Autologous Stem Cell Transplant or ASCT Ineligible pdf download Pembrolizumab (Adult Who Failed Prior Brentuximab Vedotin) - Relapsed cHL Post-ASCT or ASCT Ineligible pdf download Pembrolizumab - In Combo w Carboplatin and Paclitaxel for First-Line Metastatic Squamous NSCLC pdf download Pembrolizumab - In Combo w Platinum and Pemetrexed for First Line Metastatic Non-Squamous NSCLC pdf download Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer pdf download Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma pdf download Pembrolizumab - First Line Treatment of MSI-H dMMR Metastatic Colorectal Cancer pdf download Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma pdf download Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer pdf download Pembrolizumab - Previously Treated MSI-H dMMR Advanced Endometrial Cancer pdf download Pembrolizumab - In Combination with Lenvatinib for Advanced Endometrial Cancer pdf download Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma pdf download Pembrolizumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma pdf download Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma pdf download Pembrolizumab - Metastatic Persistent or Recurrent Carcinoma of the Cervix

Patient Info Sheet

avr 2023

What it is used for

  • For treating certain types of cancers such as skin (called melanoma), non-small cell lung, head and neck, renal cell (kidney), colorectal, endometrial, cervical, bladder or urinary tract, breast, esophageal and others. It is also used to treat some types of lymphomas.
  • Pembrolizumab is an immunotherapy drug. For more information on immunotherapy, click here


You might also be interested in